NOT FOR DISTRIBUTION
Header cover image

Market Cap

₪472.6m

Last Updated

2021/05/15 16:18 UTC

Data Sources

Company Financials +

Executive Summary

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has BrainsWay's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BWAY is more volatile than 75% of IL stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BWAY's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of IL stocks.


Market Performance


7 Day Return

4.3%

BWAY

-0.3%

IL Medical Equipment

-0.8%

IL Market


1 Year Return

3.1%

BWAY

68.0%

IL Medical Equipment

42.2%

IL Market

Return vs Industry: BWAY underperformed the IL Medical Equipment industry which returned 68% over the past year.

Return vs Market: BWAY underperformed the IL Market which returned 42.2% over the past year.


Shareholder returns

BWAYIndustryMarket
7 Day4.3%-0.3%-0.8%
30 Day-5.3%1.4%3.2%
90 Day-1.2%1.7%8.5%
1 Year3.1%3.1%68.8%68.0%45.5%42.2%
3 Year-14.1%-14.1%129.7%127.4%45.4%34.4%
5 Year-12.9%-12.9%95.3%91.3%89.9%62.5%

Long-Term Price Volatility Vs. Market

How volatile is BrainsWay's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BrainsWay undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BWAY (₪14.26) is trading below our estimate of fair value (₪52.78)

Significantly Below Fair Value: BWAY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BWAY is unprofitable, so we can't compare its PE Ratio to the IL Medical Equipment industry average.

PE vs Market: BWAY is unprofitable, so we can't compare its PE Ratio to the IL market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BWAY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BWAY is overvalued based on its PB Ratio (4.9x) compared to the IL Medical Equipment industry average (2.2x).


Future Growth

How is BrainsWay forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

55.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BWAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BWAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BWAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BWAY's revenue (20.3% per year) is forecast to grow faster than the IL market (7.5% per year).

High Growth Revenue: BWAY's revenue (20.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BWAY's Return on Equity is forecast to be high in 3 years time


Past Performance

How has BrainsWay performed over the past 5 years?

-22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BWAY is currently unprofitable.

Growing Profit Margin: BWAY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BWAY is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.

Accelerating Growth: Unable to compare BWAY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BWAY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (29.7%).


Return on Equity

High ROE: BWAY has a negative Return on Equity (-27.43%), as it is currently unprofitable.


Financial Health

How is BrainsWay's financial position?


Financial Position Analysis

Short Term Liabilities: BWAY's short term assets ($24.3M) exceed its short term liabilities ($6.8M).

Long Term Liabilities: BWAY's short term assets ($24.3M) exceed its long term liabilities ($7.6M).


Debt to Equity History and Analysis

Debt Level: BWAY is debt free.

Reducing Debt: BWAY has no debt compared to 5 years ago when its debt to equity ratio was 1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BWAY has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if BWAY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is BrainsWay current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BWAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BWAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BWAY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BWAY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BWAY's dividend in 3 years as they are not forecast to pay a notable one for the IL market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Chris von Jako (51 yo)

1.33yrs

Tenure

Dr. Christopher R. von Jako, Ph.D., also know as chris, Serves as President and Chief Executive Officer of Brainsway Ltd. Since January 2020. He serves as an Independent Director of NinePoint Medical, Inc....


Leadership Team

Experienced Management: BWAY's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: BWAY's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 49%.


Top Shareholders

Company Information

BrainsWay Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BrainsWay Ltd.
  • Ticker: BWAY
  • Exchange: TASE
  • Founded: 2003
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: ₪472.611m
  • Shares outstanding: 33.14m
  • Website: https://www.brainsway.com

Number of Employees


Location

  • BrainsWay Ltd.
  • Bynet Building
  • 3rd Floor
  • Jerusalem
  • 9777518
  • Israel

Listings


Biography

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic s...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 16:18
End of Day Share Price2021/05/13 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.